

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-107. [Cancelled]

Claim 108. [Previously Presented] A mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959.

Claim 109. [Previously Presented] An antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof.

Claim 110. [Previously Presented] The antibody of claim 109 which is a F(ab')₂ fragment.

Claim 111. [Previously Presented] The antibody of claim 109 which is a F(ab') fragment.

- Claim 112. [Withdrawn] The antibody of claim 109 which is conjugated to a therapeutic agent.
- Claim 113. [Withdrawn] The antibody of claim 112, wherein the therapeutic agent is a cytotoxin.
- Claim 114. [Previously Presented – Withdrawn] The antibody of claim 113 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, a glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.
- Claim 115. [Withdrawn] The antibody of claim 109 comprising at least one modification in the Fc region.
- Claims 116-122. [Cancelled]
- Claim 123. [Previously Presented] A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen-binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.
- Claims 124-130. [Cancelled]

- Claim 131. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.
- Claim 132. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a humanized version, or antigen-binding fragment thereof.
- Claim 133. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a F(ab')₂ fragment.
- Claim 134. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a F(ab') fragment.
- Claim 135. **[Previously Presented]** The antibody of claim 109, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.
- Claim 136. **[Previously Presented]** The antibody of claim 109, wherein said antibody is a humanized version, or antigen-binding fragment thereof.